What are the current guidelines for diagnosing and managing osteoporosis in adults?

Osteoporosis Guidelines: Diagnosis and Management in Adults

Diagnosis and Screening

All postmenopausal women ≥65 years, men >70 years, and adults ≥50 years with risk factors should undergo bone mineral density (BMD) testing using dual-energy x-ray absorptiometry (DXA) at the lumbar spine, total hip, femoral neck, and if indicated, one-third radius. 1

Key Diagnostic Criteria

• Osteoporosis is diagnosed when T-score ≤-2.5 at the lumbar spine, femoral neck, total hip, or one-third radius (use the lowest T-score at any measured site) 1
• Low-trauma major fractures (hip, spine, forearm, humerus, pelvis) establish the diagnosis of osteoporosis regardless of BMD 1
• Use NHANES III reference database for T-score calculation based on 20-29 year-old White women 1

Risk Factors Requiring Assessment

Critical risk factors include: advanced age, current smoking, excessive alcohol consumption (≥3 drinks daily), prior fragility fracture, parental hip fracture history, low body weight, glucocorticoid use, hypogonadism, impaired mobility, increased fall risk, and postmenopausal status 1

Vertebral Fracture Assessment

Perform vertebral fracture assessment (VFA) via DXA or standard radiography in patients ≥50 years with T-score <-1.0, historical height loss >4 cm, self-reported vertebral fracture, or long-term glucocorticoid therapy 1

Fracture Risk Assessment Tools

• FRAX (WHO Fracture Risk Assessment Tool) should be used for adults ≥40 years to quantify 10-year fracture probability 1
• FRAX is not validated for patients <40 years or for reassessment during therapy 1
• Treatment thresholds: 10-year probability ≥20% for major osteoporotic fractures or ≥3% for hip fractures 1

Important caveat: FRAX does not incorporate falls, number/timing of fractures, or frailty—clinical judgment must supplement tool-based assessment 1

Non-Pharmacologic Management

Universal Recommendations for All Patients

• Calcium intake: 1,000-1,200 mg/day (dietary plus supplemental if needed) 1
• Vitamin D: 800-1,000 IU/day minimum 1
• Exercise: Combination of balance training, flexibility/stretching, endurance, and resistance/progressive strengthening exercises 1
• Smoking cessation and alcohol limitation (≤1-2 drinks/day) 1
• Weight-bearing exercise and maintaining recommended body weight 1

Pharmacologic Treatment

Risk Stratification and Treatment Algorithm

Very High Fracture Risk (3-year fracture risk ≥10%):

• First-line: Anabolic agents (teriparatide, abaloparatide, or romosozumab) 2, 3, 4
• These are conditionally recommended over antiresorptive agents (bisphosphonates or denosumab) 1

High Fracture Risk:

• First-line: Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are strongly recommended 1
• Alternative options (if oral bisphosphonates inappropriate): Denosumab 60 mg subcutaneously every 6 months or IV zoledronic acid 5 mg annually 1
• For adults ≥40 years at high risk, denosumab or PTH/PTHrP are conditionally recommended over bisphosphonates 1

Moderate Fracture Risk (3-year fracture risk >3%):

• Oral or IV bisphosphonates, denosumab, or PTH/PTHrP are all conditionally recommended 1
• Choice based on patient factors: adherence potential, GI tolerability, cost, and safety profile 1

Specific Treatment Considerations

Oral Bisphosphonates:

• Alendronate 70 mg once weekly or risedronate 35 mg once weekly 1
• Ibandronate 150 mg once monthly 1
• Challenge: GI adverse effects may limit adherence 1

IV Bisphosphonates:

• Zoledronic acid 5 mg once yearly for osteoporosis 1
• May cause acute phase response (fever, myalgias) within first week—pretreat with acetaminophen or ibuprofen 1

Denosumab:

• 60 mg subcutaneously every 6 months 1
• Critical warning: Risk of rebound vertebral fractures upon discontinuation—must transition to bisphosphonate therapy 1
• Lack of safety data in immunosuppressed patients 1

Anabolic Agents:

• Teriparatide or abaloparatide: Daily subcutaneous injections 1
• Romosozumab: Dual-action agent 1, 5
• Sequential therapy required after discontinuation to prevent bone loss 1

Hormone Replacement Therapy:

• Now recommended as first-line option in younger postmenopausal women with high fracture risk and low baseline risk for adverse events 2
• Generally avoided in hormone-responsive cancers 1

Raloxifene:

• Reserved for postmenopausal women when other agents are inappropriate 1
• Strong recommendation AGAINST using menopausal estrogen therapy, estrogen plus progestogen, or raloxifene as primary osteoporosis treatment in most women 1

Treatment Duration and Monitoring

• Follow-up BMD testing intervals: 1-5 years after starting or changing therapy, depending on clinical circumstances 1
• Do NOT perform routine BMD monitoring during the first 5 years of pharmacologic treatment 1
• Each facility should determine precision error and calculate least significant change (LSC) 1
• Follow-up should ideally occur at the same facility with the same DXA system 1

Sequential Therapy Strategy

Critical principle: Sequential treatment is mandatory to prevent rebound bone loss and vertebral fractures after discontinuation of denosumab, romosozumab, and PTH/PTHrP 1

Special Populations

Glucocorticoid-Induced Osteoporosis (GIOP)

For adults on ≥2.5 mg/day prednisone equivalent for >3 months:

• Screening within 6 months of initiation: FRAX (age ≥40), BMD with VFA or spine x-rays 1
• For prednisone >7.5 mg daily, apply FRAX glucocorticoid correction 1
• All patients with medium, high, or very high fracture risk should receive osteoporosis therapy 1
• Oral bisphosphonates strongly recommended for high/very high risk 1

Cancer Survivors

Patients on aromatase inhibitors, androgen deprivation therapy, or GnRH agonists:

• Offer bone-modifying agents if T-score ≤-2.5 or FRAX-estimated 10-year risk ≥20% major fractures or ≥3% hip fractures 1
• Options: oral bisphosphonates, IV bisphosphonates, or denosumab at osteoporosis-indicated dosage 1
• BMD testing every 2 years or more frequently if near treatment threshold 1

Adults <40 Years

• Low risk: Optimize calcium/vitamin D and lifestyle modifications over pharmacologic treatment 1
• Moderate-to-high risk: Oral bisphosphonates conditionally recommended 1
• Use Z-scores (not T-scores); Z-score ≤-2.0 indicates low bone mass for age 1

Common Pitfalls

• Failing to transition patients off denosumab, romosozumab, or PTH/PTHrP to bisphosphonates risks severe rebound vertebral fractures 1
• FRAX underestimates risk with very high glucocorticoid doses (≥30 mg/day prednisone) 1
• Relying solely on BMD without assessing clinical risk factors misses many patients who will fracture 1
• Using IV bisphosphonates in low-risk patients <40 years exposes them to unnecessary harm 1
• Prescribing denosumab to immunosuppressed patients without adequate safety data 1